Aclidinium bromide vs Olodaterol/tiotropium bromide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide · Tudorza Pressair
Marketed by Azurity Pharmaceuticals and partners
NCT00363896 · Phase 3 · completed
The trial randomized 843 participants to double-blind aclidinium or placebo, with trough FEV1 at 12 and 28 weeks, an accepted lung-function endpoint for COPD, as its primary outcome. The registry posts no significance test, but the publication of ACCLAIM/COPD I reports trough FEV1 improvements over placebo of 61 mL and 67 mL at 12 and 28 weeks (both p<0.001).
Reported efficacy
Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L. (met)
Result source: NCT03022097
Olodaterol/tiotropium bromide
Marketed by Boehringer Ingelheim
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aclidinium bromide | Olodaterol/tiotropium bromide |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | 0.4 vs 0.6−0.1 vs placeboNCT01966107 | —Not reported |
| Trough FEV1, change | 0.1 vs -0.1+0.2 vs placeboNCT0302209725 other results
| —Not reported |
| SGRQ total, change | -3.6 vs -1.9−1.8 vs placeboNCT015727927 other results
| —Not reported |
| TDI focal score | 2.9 vs 2.1+0.8 vs placeboNCT030220975 other results
| —Not reported |
Moderate or severe exacerbations, annualised rate
- Aclidinium bromide
- 0.4 vs 0.6−0.1 vs placeboNCT01966107
- Olodaterol/tiotropium bromide
- —Not reported
Trough FEV1, change
- Aclidinium bromide
- 0.1 vs -0.1+0.2 vs placeboNCT03022097
25 other results
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT01001494
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT01462942
- 1.2 vs 1.2 NCT00358436
- 1.2 vs 1.2 NCT00358436
- 0.1 vs -0.0 NCT00891462
- 0.1 vs -0.0 NCT01045161
- 0.1 vs -0.0 NCT01001494
- 0.0 vs -0.1 NCT01001494
- 0.1 vs -0.0 NCT00891462
- 0.0 vs -0.0 NCT01045161
- 0.0 vs -0.0 NCT01001494
- 0.1 vs 0.1 NCT02796677
- 0.0 vs -0.1 NCT01572792
- 0.0 vs -0.1 NCT01572792
- 0.1 vs -0.0 NCT00500318
- 0.1 vs -0.0 NCT02153489
- 0.1 vs -0.0 NCT01120093
- 0.1 vs -0.0 NCT01120093
- 0.1 vs -0.0 NCT01120093
- Olodaterol/tiotropium bromide
- —Not reported
SGRQ total, change
- Aclidinium bromide
- -3.6 vs -1.9−1.8 vs placeboNCT01572792
7 other results
- -5.5 vs -1.9 NCT01572792
- -8.7 vs -4.7 NCT03022097
- -7.6 vs -4.7 NCT03022097
- -6.6 vs -2.2 NCT01437397
- -5.9 vs -2.2 NCT01437397
- -7.2 vs -6.5 NCT01462942
- -8.3 vs -6.5 NCT01462942
- Olodaterol/tiotropium bromide
- —Not reported
TDI focal score
- Aclidinium bromide
- 2.9 vs 2.1+0.8 vs placeboNCT03022097
5 other results
- 2.6 vs 2.1 NCT03022097
- 2.0 vs 0.6 NCT01437397
- 2.0 vs 0.6 NCT01437397
- 2.5 vs 1.2 NCT01462942
- 2.4 vs 1.2 NCT01462942
- Olodaterol/tiotropium bromide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Olodaterol/tiotropium bromide: registry results are on file for Chronic Obstructive Pulmonary Disease, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Aclidinium bromide: 4 of 4 rows · Olodaterol/tiotropium bromide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aclidinium bromide |
|---|---|
| Dropout rate | 14.2%200 μg Once-dailya NCT00363896 · Phase 3 · monotherapy show 34 more results25.7%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 7.1%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.9%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 —400 μg Bid NCT01120093 · Phase 2 —200 μg Bid NCT01120093 · Phase 2 —100 μg Bid NCT01120093 · Phase 2 12.6%400µg NCT00891462 · Phase 3 17.8%200µg NCT00891462 · Phase 3 —400 μg NCT01045161 · Phase 3 —400 μg NCT01045161 · Phase 3 —200 μg NCT01045161 · Phase 3 —200 μg to 400 μg NCT01045161 · Phase 3 6.3%400 μg Bid NCT01001494 · Phase 3 8.7%200 μg Bid NCT01001494 · Phase 3 44.3% NCT01966107 · Phase 4 4.4%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence —400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 19.5%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 18.3%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 19.5%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 18.3%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 8.8%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 10.5%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence —400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 2.9%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 44.7%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 42.6%200µg NCT01044459 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 5.8% NCT00500318 · Phase 3 · registry result, not featured evidence —400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.8%200 μg Once-dailya NCT00363896 · Phase 3 · monotherapy show 34 more results4.8%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 1.5%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.1%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 —400 μg Bid NCT01120093 · Phase 2 —200 μg Bid NCT01120093 · Phase 2 —100 μg Bid NCT01120093 · Phase 2 3.7%400µg NCT00891462 · Phase 3 4.3%200µg NCT00891462 · Phase 3 —400 μg NCT01045161 · Phase 3 —400 μg NCT01045161 · Phase 3 —200 μg NCT01045161 · Phase 3 —200 μg to 400 μg NCT01045161 · Phase 3 1.5%400 μg Bid NCT01001494 · Phase 3 2.9%200 μg Bid NCT01001494 · Phase 3 — NCT01966107 · Phase 4 1.5%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence —400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 6.2%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.5%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.2%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 6.5%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 3.1%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 2.6%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence —400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 1.8%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 6.8%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 7.1%200µg NCT01044459 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 3.5% NCT00500318 · Phase 3 · registry result, not featured evidence —400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 8%200 μg Once-dailya NCT00363896 · Phase 3 · monotherapy show 34 more results10.3%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 7.9%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.2%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.4%400 μg Bid NCT01120093 · Phase 2 1.4%200 μg Bid NCT01120093 · Phase 2 0%100 μg Bid NCT01120093 · Phase 2 3.2%400µg NCT00891462 · Phase 3 4.3%200µg NCT00891462 · Phase 3 4.5%400 μg NCT01045161 · Phase 3 9.5%400 μg NCT01045161 · Phase 3 6%200 μg NCT01045161 · Phase 3 13%200 μg to 400 μg NCT01045161 · Phase 3 5.6%400 μg Bid NCT01001494 · Phase 3 4.3%200 μg Bid NCT01001494 · Phase 3 22.8% NCT01966107 · Phase 4 1.5%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence 0%400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence 7.3%400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 7.7%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.9%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 5.7%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 5.4%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 6%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 4.7%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence 0%400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 1.8%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 10%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 9.3%200µg NCT01044459 · Phase 3 · registry result, not featured evidence 12.3%400 μg NCT00970268 · Phase 3 · registry result, not featured evidence 15.2%400 μg NCT00970268 · Phase 3 · registry result, not featured evidence 14%200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 15.9%200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 2.3% NCT00500318 · Phase 3 · registry result, not featured evidence 0%400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 200 μg Once-dailya nasopharyngitis 16.3% (placebo 14.4%) headache 11.3% (placebo 12.5%) back pain 4.8% (placebo 4.6%) NCT00363896 · Phase 3 · monotherapy show 34 more results200 μg once-daily headache 14.2% (placebo 12.7%) nasopharyngitis 12.7% (placebo 11.3%) upper respiratory tract infection 10.8% (placebo 9.8%) NCT00358436 · Phase 3 · monotherapy 400 μg upper respiratory tract infection 9.4% (placebo 8.9%) chronic obstructive pulmonary disease 7.9% (placebo 13%) NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg upper respiratory tract infection 11.8% (placebo 8.9%) chronic obstructive pulmonary disease 9.5% (placebo 13%) NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400 μg copd exacerbation 13% (placebo 11.5%) upper respiratory tract infection 1.7% (placebo 0.5%) nasopharyngitis 1.1% (placebo 0%) NCT01045161 · Phase 3 400 μg copd exacerbation 27.9% (placebo 11.5%) upper respiratory tract infection 5.4% (placebo 0.5%) nasopharyngitis 4.1% (placebo 0%) NCT01045161 · Phase 3 200 μg copd exacerbation 8.7% (placebo 11.5%) upper respiratory tract infection 1.6% (placebo 0.5%) nasopharyngitis 1.1% (placebo 0%) NCT01045161 · Phase 3 200 μg to 400 μg copd exacerbation 22.7% (placebo 11.5%) nasopharyngitis 5.8% (placebo 0%) upper respiratory tract infection 5.8% (placebo 0.5%) NCT01045161 · Phase 3 400 μg Bid chronic obstructivce pulmonary disease 14.1% (placebo 20.5%) headache 12.3% (placebo 8.1%) nasopharyngitis 11.2% (placebo 8.4%) NCT01001494 · Phase 3 200 μg Bid chronic obstructivce pulmonary disease 15.9% (placebo 20.5%) nasopharyngitis 11.6% (placebo 8.4%) headache 10.8% (placebo 8.1%) NCT01001494 · Phase 3 urinary tract infection 5% (placebo 4.7%) upper respiratory tract infection 4.8% (placebo 5.6%) viral upper respiratory tract infection 4.4% (placebo 3.7%) NCT01966107 · Phase 4 400 μg headache 5.2% (placebo 9.7%) nasopharyngitis 3% (placebo 6.7%) NCT02375724 · Phase 4 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary 15.6% nasopharyngitis 11.5% headache 5.1% NCT02796677 · Phase 3 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary disease 20.3% (placebo 15.8%) urinary tract infection 8.2% (placebo 5.5%) nasopharyngitis 7.7% (placebo 4.8%) NCT01572792 · Phase 3 · registry result, not featured evidence 400/6 μg chronic obstructive pulmonary disease 22.1% (placebo 15.8%) nasopharyngitis 6.9% (placebo 4.8%) urinary tract infection 6.4% (placebo 5.5%) NCT01572792 · Phase 3 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary disease 15.2% (placebo 17.5%) cough 5.1% (placebo 3.6%) nasopharyngitis 4.8% (placebo 3.6%) NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 400/6 μg chronic obstructive pulmonary disease 14.7% (placebo 17.5%) nasopharyngitis 5.1% (placebo 3.6%) cough 3.9% (placebo 3.6%) NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg chronic obstructive pulmonary disease 8.6% (placebo 11.9%) nasopharyngitis 7.8% (placebo 7.2%) headache 7.5% (placebo 8.2%) NCT01462942 · Phase 3 · registry result, not featured evidence 400/6 μg chronic obstructive pulmonary disease 9.4% (placebo 11.9%) nasopharyngitis 7.9% (placebo 7.2%) headache 7.1% (placebo 8.2%) NCT01462942 · Phase 3 · registry result, not featured evidence 400 μg BID nasopharyngitis 6.3% (placebo 3.7%) NCT01471171 · Phase 3 · registry result, not featured evidence 400 µg BID nasopharyngitis 6.4% (placebo 2.4%) headache 3.5% (placebo 4.7%) NCT01462929 · Phase 3 · registry result, not featured evidence 400µg chronic obstructive pulmonary disease 19.9% NCT01044459 · Phase 3 · registry result, not featured evidence 200µg chronic obstructive pulmonary disease 19.3% NCT01044459 · Phase 3 · registry result, not featured evidence 400 μg chronic obstructive pulmonary disorder 22.6% nasopharyngitis 9.4% urinary tract infection 7.5% NCT00970268 · Phase 3 · registry result, not featured evidence 400 μg chronic obstructive pulmonary disorder 30.4% contusion 10.9% cough 8.7% NCT00970268 · Phase 3 · registry result, not featured evidence 200 μg chronic obstructive pulmonary disorder 24.7% nasopharyngitis 8.6% back pain 7.5% NCT00970268 · Phase 3 · registry result, not featured evidence 200 μg chronic obstructive pulmonary disorder 36.4% sinusitis 11.4% upper respiratory tract infection 11.4% NCT00970268 · Phase 3 · registry result, not featured evidence cough 5.8% (placebo 3.2%) headache 5.8% (placebo 7.4%) upper respiratory tract infection 5.8% (placebo 2.1%) NCT00500318 · Phase 3 · registry result, not featured evidence 400 μg Bid diarrhoea 6.9% (placebo 0%) chronic obstructive pulmonary disease 0% (placebo 10%) NCT00868231 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 31 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aclidinium bromide
show 1 more result
show 3 more results
show 25 more results
show 8 more results
show 8 more results
show 5 more results
show 7 more results
show 4 more results
show 5 more results
show 5 more results
+ 30 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide's landscape · Olodaterol/tiotropium bromide's landscape